Complete Pathologic Response When Adding Pembrolizumab to Neoadjuvant Chemotherapy in Stage IIIA Non-Small-Cell Lung Cancer

J Oncol Pract. 2018 Sep;14(9):569-571. doi: 10.1200/JOP.18.00127. Epub 2018 Jul 25.

Authors

Addie Hill¹, Jun Gong¹, Sharon Wilczynski¹, Rizvan Mirza¹, Loretta Erhunmwunsee¹, Ravi Salgia¹

Affiliation

¹ City of Hope Cancer Center, Duarte, CA.

PMID: 30044685
DOI: 10.1200/JOP.18.00127

No abstract available

Publication types

Case Reports

MeSH terms

Antibodies, Monoclonal, Humanized / therapeutic use*
Antineoplastic Agents, Immunological / therapeutic use*
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Carboplatin / therapeutic use
Carcinoma, Non-Small-Cell Lung / diagnostic imaging
Carcinoma, Non-Small-Cell Lung / drug therapy*
Carcinoma, Non-Small-Cell Lung / pathology
Carcinoma, Non-Small-Cell Lung / surgery
Female
Humans
Lung Neoplasms / diagnostic imaging
Lung Neoplasms / drug therapy*
Lung Neoplasms / pathology
Lung Neoplasms / surgery
Middle Aged
Neoadjuvant Therapy*
Neoplasm Staging
Pemetrexed / therapeutic use
Tomography, X-Ray Computed
Treatment Outcome

Substances

Antibodies, Monoclonal, Humanized
Antineoplastic Agents, Immunological
Pemetrexed
Carboplatin
pembrolizumab